Amgen

YTD

ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

31,500

Employees31,500

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

31,500

Employees31,500

AMGN Key Statistics

Market cap

188.58B

Market cap188.58B

Price-Earnings ratio

23.90

Price-Earnings ratio23.90

Dividend yield

2.84%

Dividend yield2.84%

Average volume

2.45M

Average volume2.45M

High today

$351.33

High today$351.33

Low today

$342.35

Low today$342.35

Open price

$345.04

Open price$345.04

Volume

2.67M

Volume2.67M

52 Week high

$391.29

52 Week high$391.29

52 Week low

$261.43

52 Week low$261.43

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $349.20. The company's market cap stands at 188.58B, with a P/E ratio of 23.90 and a dividend yield of 2.8%.

On 2026-04-08, Amgen(AMGN) stock moved within a range of $342.35 to $351.33. With shares now at $349.20, the stock is trading +2.0% above its intraday low and -0.6% below the session's peak.

Trading volume for Amgen(AMGN) stock has reached 2.67M, versus its average volume of 2.45M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $391.29 and a low of $261.43.

AMGN News

Simply Wall St 8h

Amgen’s Tepezza On Body Injector Data Tests Thyroid Eye Disease Moat

Amgen has reported positive Phase 3 results for a new subcutaneous, on-body injector formulation of Tepezza for Thyroid Eye Disease. The late stage trial found...

TipRanks 10h

Amgen price target raised to $325 from $319 at Truist

Truist raised the firm’s price target on Amgen (AMGN) to $325 from $319 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 e...

TipRanks 11h

Viridian Therapeutics price target lowered to $31 from $37 at Wedbush

Wedbush analyst Laura Chico lowered the firm’s price target on Viridian Therapeutics (VRDN) to $31 from $37 and keeps an Outperform rating on the shares. The fi...

Analyst ratings

51%

of 37 ratings

Buy

40.5%

Hold

51.4%

Sell

8.1%

More AMGN News

TipRanks 1d

Amgen put volume heavy and directionally bearish

Bearish flow noted in Amgen (AMGN) with 3,010 puts trading, or 1.5x expected. Most active are May-26 345 puts and Apr-26 320 puts, with total volume in those st...

TipRanks 2d

Amgen announces ‘positive’ results from Phase 3 trial of tepezza

Amgen (AMGN) announced positive topline results from a Phase 3 trial of tepezza administered by subcutaneous injection via an on-body injector in participants w...

TipRanks 5d

Amgen Expands Thyroid Eye Disease Bet With New AMG 732 Rollover Study

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

TipRanks 6d

Amgen Terminates Early-Stage AMG 378 Study: What Investors Should Watch Next

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.